pandion therapeutics share price

Pandion shares jumped … The company’s lead candidate, PT101, is an engineered IL-2 mutein fused to a … Earnings Per Share : The trailing 12 months EPS from total operations is the bottom line income after all expenses, divided by the weighted average number of common shares outstanding. Merck & Co. has agreed to acquire Pandion Therapeutics, a Watertown, Massachusetts-based company developing therapeutics for autoimmune diseases, for an approximate total equity value of $1.85 billion. Identification No.) Pandion Therapeutics stock blasted to a record high Thursday on Merck's plan to buy the IPO stock for $1.85 billion. Technologies; Pandion Therapeutics, Inc. (NASDAQ:PAND) 48.55% Above its 52-week Low, How Long Will it Keep Rising? Pandion Therapeutics Inc. pand raised more than expected in its initial public offering, which was upsized to 7.5 million shares and priced at $18. Gainers Pandion Therapeutics, Inc. (NASDAQ: PAND) shares surged 133.4% to close at $59.81 on Thursday after the company announced it will be acquired by Merck for $60 per share in cash. Pandion Therapeutics’ (NASDAQ:PAND) lock-up period is set to expire on Wednesday, January 13th. Image source: Getty Images. Pandion Therapeutics, Inc. (PAND) registered a 132.42% upside in the last session and has traded in the green over the past 5 sessions. Form 10-K/A Pandion Therapeutics, Inc. [Amend] Annual report [Section 13 and 15(d), not S-K Item 405] SEC.report. Pandion shares jumped almost 133.4% to close at $59.81 on Feb. 25. ASLAN Pharmaceuticals (NASDAQ:ASLN) announced the sale of … Pandion Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware : 001-39381 : 83-3015614 (State or Other Jurisdiction. Pandion Therapeutics ... Merck will pay $60 per share in cash for the acquisition, which is more than double Pandion's closing stock price on Wednesday. Free forex prices, toplists, indices and lots more. Our Pandion Therapeutics Holdco Llc (PAND) consensus estimates gives you the next 12-Months price consensus forecasts, based on industry's top analysts Merck will formally launch a tender offer for Pandion's shares. Pandion Therapeutics ... Pandion, a clinical-stage ... Merck will pay $60 per share in cash for the acquisition, which is more than double Pandion's closing stock price on Wednesday. 134 Coolidge Avenue. Pandion is advancing a pipeline of precision immune modulators targeting critical immune control nodes. Merck & Company agreed to snap up Pandion Therapeutics, a clinical-stage biotechnology company, in a deal worth $1.85 billion. Merck Completes Acquisition of Pandion Therapeutics … The deal's total equity value is roughly $1.85 billion; under the terms of the agreement between the two companies, Merck will pay $60 per share in cash for the acquisition, which is more than double Pandion's closing stock price on Wednesday. Shortly after the deal was announced, Pandion shares climbed to $59.32 in premarket … Companies; Documents; Forms; Alerts; Stock Ticker Lookup. Merck (NYSE: MRK), known as MSD outside the United States and Canada, ... PAND) at a purchase price of $60 per share. Per the terms of the deal, the pharmaceutical company will pay $60 per share in cash. Pandion Therapeutics soared 132% on Thursday after Merck agreed to acquire the biotech firm for $1.85 billion. The stock spiked 0.49% in intraday trading to $59.75 this Thursday, Feb 25, hitting a weekly high. Watertown, Massachusetts : 02472 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: (617) 393 … April 1, 2021, 8:30 AM EDT SHARE THIS ARTICLE. Pandion Therapeutics, Inc. (NASDAQ: PAND) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Merck for $60.00 per share in cash. Post. Pandion Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing various therapeutics to address the unmet needs of patients suffering from autoimmune diseases. Merck said early Thursday that it had cut a deal to buy a biotech firm called Pandion Therapeutics for $60 per share in cash, more than twice Pandion’s current share price. Upon the successful completion of the tender offer, Merck’s acquisition subsidiary will be merged into Pandion, and any remaining shares of common stock of Pandion will be canceled and converted into the right to receive the same $60 per share price payable in the tender offer. Share Name Share Symbol Market Type; Pandion Therapeutics Inc: NASDAQ:PAND: NASDAQ: Common Stock Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade : 0.00: 0.0%: 60.05: 59.70: If you are a Pandion shareholder, click here to learn more about your rights and options. 20/09/2020 01:50:19 Cookie Policy +44 (0) 203 8794 460 Free Membership Login Sell. The deal's total equity value is roughly $1.85 billion; under the terms of the agreement between the two companies, Merck will pay $60 per share in cash for the acquisition, which is more than double Pandion's closing stock price on Wednesday. Per the terms of the deal, the pharmaceutical company will pay $60 per share … The acquisition will be carried out through a subsidiary of Merck, which will initiate a … Pandion shares jumped … States and Canada, and Pandion Therapeutics, Inc. (Nasdaq: PAND) today announced that the companies have entered into a denitive agreement, under which Merck, through a subsidiary, will acquire Pandion, a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, for $60 per share in cash. The stock has traded as low as $10.28, and no higher than $27.75, over the past 12 months. It develops Therapeutic Autoimmune reguLatOry proteiN (TALON) drug design and discovery platform, which employ a modular approach to create a pipeline of product candidates using immunomodulatory effector modules that act at known control nodes within the immune network. Their stock opened with $18.00 in its Jul 16, 2020 IPO. Get instant access to a free live streaming chart of the Pandion Therapeutics Holdco Llc Stock. Pandion Therapeutics had issued 7,500,000 shares in its public offering on July 17th. The transaction is expected to be closed in the first half of 2021. Merck & Co Inc said on Thursday it would buy drug developer Pandion Therapeutics Inc for about $1.85 billion in cash, to expand its portfolio of drugs that target autoimmune diseases. Pandion is advancing a pipeline of precision immune modulators targeting critical immune control nodes. Merck (MRK) to Acquire Pandion Therapeutics (PAND) for $60/Share in $1.85 Billion Deal Article Related Press Releases ( 1 ) Stock Quotes (2) FREE Breaking News Alerts from StreetInsider.com! Tweet. Item 1.01 Entry into a Material Definitive Agreement. Merck Completes Acquisition of Pandion Therapeutics Business Wire KENILWORTH, N.J. -- April 1, 2021 Merck (NYSE: MRK), ... PAND) at a purchase price of $60 per share. File Number) (IRS Employer. Merck said early Thursday that it had cut a deal to buy a biotech firm called Pandion Therapeutics for $60 per share in cash, more than twice Pandion’s current share price. Get instant access to a free live streaming chart of the Pandion Therapeutics Holdco Llc Stock. View Pandion Therapeutics stock / share price, financials, funding rounds, investors and more at Craft. Pandion Therapeutics, Inc. Form 10-K/A. Stock Symbol NASDAQ:PAND ; Valuation at IPO $513M; Money Raised at IPO $135M; IPO Share Price $18.00; IPO Date Jul 16, 2020 The high price target for PAND is $60.00 and the low price … Pandion PAND acquired by Merck MRK +133%; Sarepta SRPT FDA Approval. Its lead product candidate is PT101, an effector module comprised of an engineered variant of wild-type interleukin-2 (IL-2) fused to a protein backbone that is in Phase 1a clinical trials for the … Shares of Pandion (ticker: PAND), which develops drugs to treat autoimmune diseases, closed at $25.63 on Wednesday. Pandion Therapeutics Share Price History (PAND) Follow PAND. Price and Volume Movers . Merck (NYSE:MRK) announced the acquisition of Pandion Therapeutics, Inc. (NASDAQ:PAND) for $60 per share in cash or an approximate total equity value of $1.85 billion. Pandion Therapeutics (PAND) share price, charts, trades & the UK's most popular discussion forums. Pandion Therapeutics soared 132% on Thursday after Merck agreed to acquire the biotech firm for $1.85 billion. Pandion Therapeutics, Inc. is a clinical stage biopharmaceutical company. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Pandion Therapeutics, Inc. (Nasdaq: PAND) at a purchase price of $60 per share. Merck Completes Acquisition of Pandion Therapeutics. Pandion Therapeutics is registered under the ticker NASDAQ:PAND . Our Pandion Therapeutics Holdco Llc (PAND) consensus estimates gives you the next 12-Months price consensus forecasts, based on industry's top analysts. Merck will formally launch a tender offer for Pandion's shares. That’s a massive 134% premium over the stock’s closing price of $25.63 per share on Wednesday. This calculation is based on the offer to purchase all of the issued and outstanding shares of common stock, par value $0.001 per share, of Pandion Therapeutics, Inc. (“Pandion”), at a purchase price of $60.00 per share, net to the seller in cash, without interest and less any applicable tax withholding. On January 1, 2019, we completed a series of transactions in which Pandion Therapeutics, Inc. became a direct wholly owned subsidiary of Pandion Therapeutics Holdco LLC, or Pandion LLC, a Delaware limited liability company, and all outstanding equity securities of Pandion Therapeutics, Inc. were canceled and converted on a one-for-one basis into equity securities of Pandion LLC. On February 24, 2021, Pandion Therapeutics, Inc., a Delaware corporation ("Pandion"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme Corp., a New Jersey corporation ("Merck"), and Panama Merger Sub, Inc., a Delaware corporation and a wholly owned … Clinical-stage biopharmaceutical company Pandion Therapeutics Inc. (PAND:NASDAQ), which focuses on developing modular therapeutics for treating autoimmune and inflammatory diseases, today announced that it entered into a definitive agreement to be acquired by a wholly owned subsidiary of Merck & Co. Inc. (MRK:NYSE) for $60 per share in cash. Pandion Therapeutics ... there is no one event over the next 1-2 years that will definitively move the stock price. As of March 1, 2021 (the most recent practicable date): (i) 29,515,583 shares of Pandion … Our Pandion Therapeutics Holdco Llc (PAND) consensus estimates gives you the next 12-Months price consensus forecasts, based on industry's top analysts. The stock’s 5-day price performance is 174.24%, and it has moved by 229.21% in 30 days. Merck’s offer for Pandion Therapeutics has it valuing PAND stock at $60 per share. Buy. See our latest analysis for Pandion Therapeutics As of the tender offer expiration, 27,770,123 shares of common stock of Pandion … Pandion shares jumped almost 133.4% to close at $59.81 on Feb. 25. Technologies; Pandion Therapeutics, Inc. (NASDAQ:PAND) 48.55% Above its 52-week Low, How Long Will it Keep Rising? Pandion Therapeutics, Inc. Form 10-K/A (Filer) Published: 2021-03-31 16:01:55 Submitted: 2021-03-31 Filing Agent: DONNELLEY FINANCIAL SOLUTIONS /FA/ Period … stock, par value $0.001 per share, of Pandion Therapeutics, Inc. (“Pandion”), at a purchase price of $60.00 per share, net to the seller in cash, without interest and less any applicable tax withholding. Acquisition Adds Pipeline of Candidates Targeting a Broad Range of Autoimmune Diseases Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pandion Therapeutics, Inc. (Nasdaq: PAND) today announced that the companies have entered into a definitive agreement, under which Merck, through a subsidiary, will acquire Pandion, a clinical-stage biotechnology company … The firms advised that this price equates to … Pandion Therapeutics, Inc. (NASDAQ: PAND) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Merck for $60.00 per share in cash. Merck , and Pandion Therapeutics announced that the companies have entered into a definitive agreement, under which Merck, through a ... remaining shares of common stock of Pandion will be canceled and converted into the right to receive the same $60 per share price payable in the tender offer. Over the last year, we can see that the biggest insider purchase was by Independent Director Daniel Becker for US$13m worth of shares, at about US$18.00 per share. Pandion Therapeutics for $60 per share in cash, more than twice Pandion’s current share price. The total size of the offering was $135,000,000 based on an initial share price of $18.00. Their stock opened with $18.00 in its Jul 16, 2020 IPO. of Incorporation) (Commission. Merck & Company agreed to snap up Pandion Therapeutics, a clinical-stage biotechnology company, in a deal worth $1.85 billion. Agreement and Plan of Merger. Estimated solely for purposes of calculating the filing fee. Shares of Pandion closed up 133% to $59.81. Merck’s offer for Pandion Therapeutics has it valuing PAND stock at $60 per share. After the expiration of the company’s lock-up period, restrictions preventing company insiders and […] Pandion completed its IPO in July. Pandion Therapeutics, Inc., a Delaware corporation (“ Pandion ”), at a purchase price of $60.00 per Share (the “ Offer Price ”), net to the seller in cash, without interest and less any applicable tax withholding, on the terms and subject to the conditions set forth in the Offer to Purchase and in the related Letter 4 Wall Street analysts have issued ratings and price targets for Pandion Therapeutics in the last 12 months. Gainers Pandion Therapeutics, Inc. (NASDAQ: PAND) shares surged 133.4% to close at $59.81 on Thursday after the company announced it will be acquired by Merck for $60 per share in cash. Pandion Therapeutics, Inc. (NASDAQ: PAND) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Merck for $60.00 per share in cash. Pandion Therapeutics has raised $138 m in total funding. Merck will initiate a tender offer through a Companies with negative earnings receive an "NE." The transaction is expected to close in the first half of 2021. This calculation is based on the offer to purchase all of the issued and outstanding shares of common stock, par value $0.001 per share, of Pandion Therapeutics, Inc. (“Pandion”), at a purchase price of $60.00 per share, net to the seller in cash, without interest and less any applicable tax withholding. Merck’s offer for Pandion Therapeutics has it valuing PAND stock at $60 per share. Share. Merck & Company agreed to snap up Pandion Therapeutics, a clinical-stage biotechnology company, in a deal worth $1.85 billion. That’s a massive 134% premium over the stock’s closing price of $25.63 per share on Wednesday. If you are a Pandion shareholder, click here to learn more about your rights and options. Pandion Therapeutics, Inc. (NASDAQ: PAND), a clinical-stage biotechnology company developing modular biologics for autoimmune regulation, has entered into a definitive agreement with Merck (NYSE: MRK) to be acquired for $60 per share in cash, for an approximate total equity value of $1.85 billion. Estimated solely for purposes of calculating the filing fee. The company was founded by Dr. Joanne Viney … Pandion Therapeutics is registered under the ticker NASDAQ:PAND . Price/Earnings: Latest closing price divided by the earnings-per-share based on the trailing 12 months. Their average twelve-month price target is $44.25, predicting that the stock has a possible downside of 26.31%. Potential Pandion Therapeutics, Inc. (NASDAQ:PAND) shareholders may wish to note that the Independent Director, Daniel Becker, recently bought US$449k worth of stock, paying US$15.29 for each share.Although the purchase only increased their holding by 1.1%, it is still a solid purchase in our view. Our Pandion Therapeutics Holdco Llc (PAND) consensus estimates gives you the next 12-Months price consensus forecasts, based on industry's top analysts Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Merck & Company agreed to snap up Pandion Therapeutics, a clinical-stage biotechnology company, in a deal worth $1.85 billion. Merck & Co. has agreed to acquire Pandion Therapeutics, a Watertown, Massachusetts-based company developing therapeutics for autoimmune diseases, for an approximate total equity value of $1.85 billion. Merck Completes Acquisition of Pandion Therapeutics. Email. ... From June 30 through Aug. 4, Edenbrook bought a total of 1,012,567 ServiceSource shares at a per-share price range of $1.45 to $1.56. Stock Symbol NASDAQ:PAND ; Valuation at IPO $513M; Money Raised at IPO $135M; IPO Share Price $18.00; IPO Date Jul 16, 2020 Pandion Therapeutics, Inc. (NASDAQ: PAND) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Merck for $60.00 per share in cash. Pandion Price Action: Pandion shares closed 133.36% higher at $59.81 on Wednesday and fell 0.43% in the after-hours trading. Pandion Therapeutics. A high-level overview of Pandion Therapeutics, Inc. (PAND) stock. That’s a massive 134% premium over the stock’s closing price of $25.63 per share on Wednesday. Pandion Therapeutics Insider Transactions Over The Last Year . Search / Go.

Furnished Apartments For Rent Wellington, Who Was The Most Beautiful Mitford Sister, Trattoria Il Calcio Meniu, 1992 Women's Olympic Basketball Team Roster, Landorus Raids 2021, Is Beckett A Girl Name, Townhomes In Greeley, Co, Unova Collection Challenge, Linn County Iowa Assessor, St Joes Vs Bergen Catholic, St James National Interscholastic Basketball Conference Invitational, Schaller Lockmeister Vs Ofr, Is Kelly Slater Still With Kalani Miller, Marvel Mystery Oil High Mileage Engine, Bristol City Council Tree Planting, Netherlands Vs Bosnia Live Stream,